

PERSONAL INFORMATION

Serena Marchetti

WORK EXPERIENCE

-
- 2003–2004 **Staff Member Department of Emergency Medicine**
Pistoia Hospital (Italy)
Activity in in- and out-of-hospital Emergency Medicine Department.
- 2006–2007 **Staff Member Department of Internal Medicine, section of Medical Oncology**
Campo di Marte Hospital, Lucca (Italy)
Daily care of in- and out-of-hospital patients with common oncological diseases. Interdivisional night and week-end activity of in-hospital patients attended to the Departments of Internal Medicine, Gastroenterology, or Medical Oncology.
- 2007–Present **Medical Oncologist, Clinical Assessor for Oncological products**
The Netherlands Cancer Institute; The Dutch Medicines Evaluation Board (Netherlands)
Daily care of in- and out-of-hospital patients with common oncological diseases.
Clinical assessment for the Dutch Medicines Evaluation Board regarding registration of new drugs in the field of oncology and hematology.

EDUCATION AND TRAINING

-
- 1993–1999 **Medical Doctor**
State University Florence (Italy)
Education and training in medicine and surgery.
Awarded qualification as Medical Doctor (cum laude)
- 1999–2003 **Board certified Medical Oncologist**
State University Florence (Italy)
Daily training on clinical care of patients with internal medicine diseases and training on clinical care of in- and out- of-hospital patients with common oncological diseases.
Board certified Medical Oncologist (cum laude)
- 2002–2002 **Diploma for Emergency medicine activity**
Campo di Marte Hospital, Pistoia (Italy)
Training in in- and out-of hospital medical emergencies, training course with diplomas in Basic Life Support (BLS), Basic Life Support – Defibrillation, Pediatric Basic Life Support (PBLs), Advanced Life Support (ALS), Advanced Traumatic Life Support (ATLS), according to the International Resuscitation Council (IRC)
- 2003–2007 **PhD**
State University Florence (Italy)
- 2013–2013 **PhD**
University of Utrecht (Netherlands)
- 2015– **GCP Certificate**
(Netherlands)

2019– GCP certificate renewal
(Netherlands)

ADDITIONAL INFORMATION

Expertise

Publications

- Mazzanti R, Arena U, Pantaleo P, Antonuzzo L, Cipriani G, Neri B, Giordano C, Lanini F, Marchetti S, Gentilini P. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10-year experience. *Can J Gastroenterol.* 2004 Oct;18(10):611-8.
- Lasagna N, Fantappiè O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. *Cancer Res.* 2006; 66: 2673-82.
- Oostendorp RL, Marchetti S, Beijnen JH, Mazzanti R, Schellens JHM. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate. *Cancer Chemother Pharmacol.* 2007; 59: 855-60.
- Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. *Br J Cancer.* 2007; 97: 577-81.
- Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). *Oncologist.* 2007; 12: 927-41.
- Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JHM. In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. *Mol Cancer Ther.* 2007; 6: 3307-13.
- Marchetti S, Mazzanti R, Beijnen JH, Schellens JHM. Clinical relevance: drug-drug interaction, pharmacokinetics, pharmacodynamics, and toxicity. *Drug Transporters, Molecular Characterization and role in Drug Disposition.* John Wiley & Sons. 2007; 24: 747-880.
- Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHM. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1^{-/-}/Mdr1a/1b^{-/-} (triple-knockout) and wild-type mice. *Mol Cancer Ther.* 2008; 7: 2280-7.
- Devriese LA, Witteveen PO, Marchetti S, Mergui-Roelvink M, Reyderman L, Wanders J, Jenner A, Edwards G, Beijnen JH, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment. *Cancer Chemother Pharmacol.* 2012; 70: 823-32.
- Dubbelman AC, Uthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JHM. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors. *Cancer Chemother Pharmacol.* 2012; 70: 653-63.
- Devriese LA, Mergui-Roelvink M, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Schellens JHM. Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole. *Invest New Drugs.* 2013; 31: 381-9.
- Devriese LA, Witteveen PE, Wanders J, Law K, Edwards G, Reyderman L, Copalu W, Peng F, Marchetti S, Beijnen JH, Huitema AD, Voest EE, Schellens JHM. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin. *Br J Clin Pharmacol.* 2013; 75: 507-15.
- da Rocha Dias S, Salmonson T, van Zwieten-Boot B, Jonsson B, Marchetti S, Schellens JHM, Giuliani R, Pignatti F. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. *Eur J Cancer.* 2013; 49: 1654-61.
- Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JHM, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. *Clin Cancer Res.* 2013; 19: 2084-95.
- Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JHM. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain

accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. *Invest New Drugs*. 2013; 31: 1125-35.

Marchetti S, Schellens JHM. Clinical relevance: drug-drug interaction, pharmacokinetics, pharmacodynamics, and toxicity. Update. In *Drug Transporters, Molecular Characterization and role in Drug Disposition*. John Wiley & Sons. 2013.

Moes JJ, Stuurman FE, Hendriks JJ, Marchetti S, Huitema AD, Beijnen JH, Schellens JH, Nuijen B.

Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. *Drug Deliv Transl Res*. 2013 Jun;3(3):243-51.

Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, Marchetti S, Beijnen JH, Schellens JH. The effect of *Echinacea purpurea* on the pharmacokinetics of docetaxel. *Br J Clin Pharmacol*. 2013 Sep;76(3):467-74.

Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". *Invest New Drugs*. 2014 Dec;32(6):1083-95.

Jacobs BA, Meulenaar J, Rosing H, Pluim D, Tibben MM, de Vries N, Nuijen B, Huitema AD, Beijnen JH, Schellens JH, Marchetti S. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine. *Cancer Chemother Pharmacol*. 2016 Jun;77(6):1201-7. doi: 10.1007/s00280-016-3035-5.

Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, Rosing H, Schellens JH, Beijnen JH. The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients. *J Clin Pharmacol*. 2016 Oct;56(10):1307-12.

de Weger VA, Stuurman FE, Koolen SLW, Moes JJ, Hendriks JJMA, Sawicki E, Thijssen B, Keessen M, Rosing H, Mergui-Roelvink M, Huitema ADR, Nuijen B, Beijnen JH, Schellens JHM, Marchetti S. A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir. *Clin Cancer Res*. 2019 Sep 15;25(18):5466-5474.

de Weger VA, Stuurman FE, Hendriks JJMA, Moes JJ, Sawicki E, Huitema ADR, Nuijen B, Thijssen B, Rosing H, Keessen M, Mergui-Roelvink M, Beijnen JH, Schellens JHM, Marchetti S. A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. *Eur J Cancer*. 2017 Nov;86:217-225.

Projects

Memberships

Other Relevant Information